Letter to Editor

نویسندگان

  • Tom E. Mollnes
  • Per H. Nilsson
  • Akira Andoh
چکیده

We want you to consider in detail the paper published in the January 2013 issue of Journal of Clinical Biochemistry and Nutrition, by Tomoki Aomatsu et al. entitled “Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice”. The authors have evaluated the pathophysiological role of the complement system in a mice colitis model. To study the role of complement, they have used Eculizumab, an antibody directed towards the human complement protein C5. We have two strong issues against this study, both regarding the use of the C5-neutralizing antibody, Eculizumab. 1. The Eculizumab, whose CDRs are of mouse origin, is highly specific against human C5, and has shown not to bind C5 of any other tested species. Aomatsu et al. will not neutralize C5 in the mouse when giving Eculizumab, and the effect they report from the Eculizumab is thus complement independent. To verify that Eculizumab indeed not cross-react with mouse, and that our argue is valid, we tested the complement inhibitory effect of Eculizumab in mouse serum in vitro in our laboratory, and found no effect on mouse complement activity as evaluated in CH50 using adequate controls (Fig. 1). 2. A C5-neutralizing antibody must be given in a dose at least 100 times higher than what was used by Aomatsu et al. C5 circulates in mouse plasma (male) at a level of approximately 90 μg/mL (≈ 0.5 μM). Eculizumab was given in a dose of 1 μg/body every 48 h, which corresponds to a serum concentration of approximately 5 nM. The standard antibody for neutralizing mouse C5 is the IgG1 BB5.1. The supplier recommends a dose of 40 mg mAb/kg (approx 1 mg/body) 0–2 days followed by injection twice a week. To note, however, even if they had used a sufficient dose, it would have had no effect, due to the lack of specificity as mention under item 1. We are surprised that this paper passed referees desk without noting this. We have sent two separate emails to the authors and asked for documentation that Eculizumab worked in their mice, but we have got no answer. To summarize, the effect that Aomatsu et al. report in the intervention group is not an effect of neutralization of C5. The complement system is involved in several inflammatory disorders, likely also in colitis. The nature of complement involvement in colitis has to be carefully evaluated and not to be misled by this study. Therefore, we strongly suggest you to consider retraction of this paper.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Letter to Editor: Research Culture and Research Misconduct

ACCORDING TO ARTICLE TYPE (LETTER TO EDITOR), NO NEED TO THIS.

متن کامل

Letter to editor " Applying High-quality DNA Melting Curve Analysis in Identifying Staphylococcus aureus and Methicillin-resistant Strains "

Letter to editor " Applying High-quality DNA Melting Curve Analysis in Identifying Staphylococcus aureus and Methicillin-resistant Strains "   Ramezan Ali Ataee   Professor, Department of Medical Microbiology, Faculty of Medicine, Hospital Research Development Committee, Applied Microbiology Research Center, System Biology, Poisoning Institute, Baqiyatallah University of Medical Sciences, T...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 52  شماره 

صفحات  -

تاریخ انتشار 2013